Beijing Scitop Bio-tech Co (300858) Q4 2025 earnings summary

Executive summary

• Revenue reached ¥365.92 million in 2025, up 20.85% year-over-year; net profit attributable to shareholders was ¥94.52 million, up 0.17% year-over-year.

• Food-grade probiotics, animal/plant microecological agents, and compound food additives are core businesses, with probiotics accounting for 72.3% of revenue.

• Significant R&D investment and industry leadership in probiotic strain development, with 77 R&D staff and 9.76% of revenue invested in R&D.

• Major capital projects include the ongoing construction of a food R&D and production base and a microecological agent production base.

Financial highlights

• Operating income: ¥365.92 million, up 20.85% year-over-year.

• Net profit attributable to shareholders: ¥94.52 million, up 0.17% year-over-year.

• Gross margin: 51.50%, down 6.75 percentage points year-over-year.

• Operating cash flow: ¥123.44 million, down 13.14% year-over-year.

• Basic and diluted EPS: ¥0.36, unchanged year-over-year.

• R&D expenses: ¥35.71 million, 9.76% of revenue.

Outlook and guidance

• Focus on expanding both B2B and B2C probiotic businesses, leveraging new production capacity and R&D base.

• Plans to enhance product lines in probiotics and microecological agents, and accelerate overseas market expansion.

• Continued investment in core strain R&D and industry standard-setting.